Latest Anticonvulsants Stories
Multiple Presentations Highlight Long-Term Safety, Tolerability, and Efficacy Measures, as Adjunctive Therapy for Patients with Refractory Partial-Onset Seizures SEATTLE, Dec.
-- Primary efficacy and safety data from the largest Phase 3 brivaracetam study involving 768 patients presented at the 68th Annual Meeting of the American Epilepsy Society BRUSSELS, Dec.
-- Results of Investigational Studies of Perampanel and Rufinamide Accepted as Late-Breaking Posters -- WOODCLIFF LAKE, N.J., Dec. 5, 2014 /PRNewswire/ -- Eisai Inc.
- 24 UCB-sponsored presentations including new data on VIMPAT® (lacosamide) BRUSSELS, Dec.
Global Epilepsy Market 2014-2018 profiles key players like GlaxoSmithKline plc, Pfizer Inc. and UCB SA.
Findings Presented at 43rd Annual Meeting of the Child Neurology Society MAPLE GROVE, Minn., Oct.
WOODCLIFF LAKE, N.J., Oct. 20, 2014 /PRNewswire/ -- Eisai Inc. announced today that the U.S.
RnRMarketResearch.com adds “Partial Seizure – Pipeline Review, H2 2014” to its store.
MarketOptimizer.org adds “PharmaPoint Epilepsy – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store.
NEWARK, Calif., Sept. 5, 2014 /PRNewswire/ -- Depomed, Inc.
- Having no light.
- Of or relating to the region of a body of water that is not reached by sunlight and in which photosynthesis is unable to occur.